Effect of Octreotide LAR Dose and Weight on Octreotide Blood Levels in Patients With Neuroendocrine Tumors
- 1 November 2005
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Pancreas
- Vol. 31 (4), 392-400
- https://doi.org/10.1097/01.mpa.0000186249.89081.0d
Abstract
Octreotide long acting repeatable (LAR) is widely used for the control of symptoms of functional neuroendocrine tumors. At doses of 30 mg/mo, up to 40% of patients require subcutaneous octreotide “rescue” and up to 40% of patients are given more than 30 mg of LAR/mo. Octreotide acetate binds to the sst2 receptor with an affinity (K d) of approximately 1 × 10−9 mol/L (≅1000 pg/mL), but higher (≅10,000 pg/mL) concentrations of octreotide are required to completely saturate this receptor. Octreotide blood level measurement may be useful to guide LAR therapy in symptomatic patients or in patients who have tumor growth on traditional LAR doses. We hypothesize that LAR doses of 60 mg/mo will produce blood levels of 10,000 pg/mL or greater. At identical monthly LAR doses, patients with higher weights will require more medication to achieve similar plasma octreotide levels than individuals with lower body weights. Trough plasma, serum, urine, and saliva octreotide levels were obtained from 52 patients with carcinoid syndrome receiving 20 (n = 8), 30 (n = 19), or 60 mg LAR/mo (n = 10). Octreotide levels were determined by radioimmunoassay. The mean ± SD plasma octreotide levels for patients receiving 20, 30, or 60 mg LAR/mo were 2518 ± 1020, 5241 ± 3004, and 10,925 ± 5330 pg/mL, respectively. Patient weight (kilograms) was inversely related to plasma octreotide levels. There was a significant correlation between plasma octreotide levels and octreotide levels measured in urine, saliva, and serum. Frequent measurement of octreotide levels may be useful to guide octreotide therapy in patients with poorly controlled symptoms or those patients experiencing tumor growth.Keywords
This publication has 11 references indexed in Scilit:
- Octreotide LAR doses used in clinical practice: Results from an internet survey and a clinical practiceJournal of Clinical Oncology, 2004
- Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic systemAnnals of Oncology, 2004
- Antiangiogenic Therapy with Somatostatin Receptor-Mediated in Situ RadiationThe American Surgeon, 2001
- Antitumor and Antiangiogenic Effects of Somatostatin Receptor-Targeted in Situ Radiation with 111In-DTPA-JIC 2DLJournal of Surgical Research, 2001
- Octreotide Acetate Long-Acting Formulation Versus Open-Label Subcutaneous Octreotide Acetate in Malignant Carcinoid SyndromeJournal of Clinical Oncology, 1999
- Effect of a somatostatin analog (octreotide acetate) on the growth of retinal pigment epithelial cells in cultureCurrent Eye Research, 1996
- Consensus statement: Octreotide dose titration in secretory diarrheaDigestive Diseases and Sciences, 1995
- Mechanisms of action of long-acting analogs of somatostatinRegulatory Peptides, 1993
- Somatostatin Analogue Phase I Trials in Neuroendocrine NeoplasmsActa Oncologica, 1993
- Preparation of Iodine-131 Labelled Human Growth Hormone of High Specific ActivityNature, 1962